Back to search

University of Ioannina

Αποτελεσματικότητα και ασφάλεια της αζαθειοπρίνης σε ασθενείς με ιδιοπαθή φλεγμονώδη νόσο των εντέρων στη Βορειοδυτική Ελλάδα

Abstract

dc:description

Introduction: Azathioprine is a chemical analogue of normal purines and is mainly used for its immunosuppressive effect. Despite the development of new agents for the treatment of inflammatory bowel disease, azathioprine (AZA) is widely used as monotherapy or combination therapy to induce and maintaining remission in both Crohn's disease and ulcerative colitis. The aim of this study was to investigate both the prevalence of malignancy development in IBD patients receiving AZA and the long-term safety of AZA and the management of adverse events.Methodology: Data were retrospectively extracted from the patient records of the Gastroenterology Department of the University Hospital of Ioannina from 1987 to 2020Results: The study included 222 patients with IBD treated with AZA, under regular follow-up intervals. 65.6% of IBD patients (146/222) had Crohn's disease and 34.4% had Ulcerative Colitis (76/222). The median duration of AZA administration was 51 months (range: 0-135 months). The most common AZA dose was 100 mg/day (range: 50–200 mg). The most common adverse events were gastrointestinal symptoms (8.6%, 18/222), leukopenia (2.7%, 6/222), hepatotoxicity (5.4%, 12/222) and pancreatitis (1.8%, 4/222). Two patients were diagnosed with basal cell carcinoma, while no hematologic malignancy was detected. Infections were recorded in 19 patients (8.6%) of which 6 required hospitalization.Conclusions: According to this retrospective observational study, approximately one-third of IBD patients treated with AZA experienced clinically significant adverse events during follow-up. Withdrawal or dose reduction of azathioprine was required in 47 (21%) patients.

Degree

thesis:*
Grantor dc:publisher
University of Ioannina
Year dc:date
2022

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Kourtis, Georgios
  • Κούρτης, Γεώργιος

Subjects

dc:subject × 18

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/52628

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Kourtis, Georgios; Κούρτης, Γεώργιος. Αποτελεσματικότητα και ασφάλεια της αζαθειοπρίνης σε ασθενείς με ιδιοπαθή φλεγμονώδη νόσο των εντέρων στη Βορειοδυτική Ελλάδα. University of Ioannina, 2022. http://hdl.handle.net/10442/hedi/52628